Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.

MLA

Ozono, Seiichiro, et al. “Efficacy and Safety of 3‐month Dosing Regimen of Degarelix in Japanese Subjects with Prostate Cancer: A Phase III Study.” Cancer Science, vol. 109, no. 6, June 2018, pp. 1920–29. EBSCOhost, https://doi.org/10.1111/cas.13600.

APA

Ozono, S., Tsukamoto, T., Naito, S., Horie, S., Ohashi, Y., Uemura, H., Yokomizo, Y., Fukasawa, S., Kusuoka, H., Akazawa, R., Saito, M., & Akaza, H. (2018). Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study. Cancer Science, 109(6), 1920–1929. https://doi.org/10.1111/cas.13600

Chicago

Ozono, Seiichiro, Taiji Tsukamoto, Seiji Naito, Shigeo Horie, Yasuo Ohashi, Hiroji Uemura, Yumiko Yokomizo, et al. 2018. “Efficacy and Safety of 3‐month Dosing Regimen of Degarelix in Japanese Subjects with Prostate Cancer: A Phase III Study.” Cancer Science 109 (6): 1920–29. doi:10.1111/cas.13600.